Dr. Behring holds a PhD in pharmacy and has extensive experience in evidence-based medicine and the assessment of pharmaceutical benefits. After completing her pharmacy studies and earning a doctorate in the field of cardiovascular diseases, she began her professional career as a consulting pharmacist at BARMER in Bavaria. In this role, she provided advice on the economic aspects of pharmaceutical care as well as on health policy issues.

From 2011 to 2024, Dr. Behring worked in the Pharmaceuticals Department of the Federal Joint Committee (G-BA) in Germany. Since the introduction of the Pharmaceutical Market Restructuring Act (AMNOG), she played a key role in implementing the early benefit assessment of pharmaceuticals in Germany. She was also instrumental in integrating Germany into the European health technology assessment (HTA) process and advocated for close coordination between national and European evaluation and consultation procedures.

Before studying pharmacy, Dr. Behring gained practical experience as a physiotherapist in both outpatient and inpatient care settings.

Since 2024, she has been working for the association Pharma Deutschland, where she focuses on core topics such as health technology assessment in Germany and Europe, reimbursement pricing, as well as innovation and research in the pharmaceutical sector.